Genetic Technologies EBITDA 2010-2021 | GENE
Genetic Technologies ebitda from 2010 to 2021. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Genetic Technologies Annual EBITDA
(Millions of US $) |
| 2021 |
$-5 |
| 2020 |
$-5 |
| 2019 |
$-5 |
| 2018 |
$-5 |
| 2017 |
$-6 |
| 2016 |
$-7 |
| 2015 |
$-8 |
| 2014 |
$-10 |
| 2013 |
$-14 |
| 2012 |
$-13 |
| 2011 |
$-12 |
| 2010 |
$-10 |
| 2009 |
$-9 |
Genetic Technologies Quarterly EBITDA
(Millions of US $) |
| 2021-06-30 |
|
| 2020-12-31 |
|
| 2020-06-30 |
|
| 2019-12-31 |
|
| 2019-06-30 |
|
| 2018-12-31 |
|
| 2018-06-30 |
|
| 2017-12-31 |
|
| 2017-06-30 |
|
| 2016-12-31 |
|
| 2016-06-30 |
|
| 2015-12-31 |
|
| 2015-06-30 |
|
| 2014-12-31 |
|
| 2014-06-30 |
|
| 2013-12-31 |
|
| 2013-06-30 |
|
| 2012-12-31 |
|
| 2012-06-30 |
|
| 2011-12-31 |
|
| 2011-06-30 |
|
| 2010-12-31 |
|
| 2010-06-30 |
|
| 2009-12-31 |
|
| 2009-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.020B |
$0.000B |
|
Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.
|
